22.626 articles found

Di-Vanilloyl And Tri-Vanilloyl Derivatives For Use In Anti-Cancer Therapy

KISS ROBERT, DUBOIS JACQUES, NEVE JEAN, LAMORAL-THEYS DELPHINE, DUFRASNE FRANCOIS, POTTIER LAURENT.

· 2009-10-13

Botulinum toxin B as an effective and safe treatment for neuroleptic-induced sialorrhea.

Steinlechner S, Klein C, Moser A, Lencer R, Hagenah J.

Psychopharmacology (Berl) · 2009-10-13

DOI: 10.1007/s00213-009-1689-yPMID: 19823807

Levodopa influences the regularity of the ankle joint kinematics in individuals with Parkinson's disease.

Kurz MJ, Hou JG.

J Comput Neurosci · 2009-10-13

DOI: 10.1007/s10827-009-0192-0PMID: 19823927

MicroRNAs: novel therapeutic targets in neurodegenerative diseases.

Roshan R, Ghosh T, Scaria V, Pillai B.

Drug Discov Today · 2009-10-12

DOI: 10.1016/j.drudis.2009.09.009PMID: 19822222

The effect of levodopa treatment on cerebral hemodynamics in patients with Parkinson's disease: serial transcranial Doppler studies.

Yong SW, Lee KY, Lee PH.

Parkinsonism Relat Disord · 2009-10-07

DOI: 10.1016/j.parkreldis.2009.09.003PMID: 19815447

[Pharmacological hypotheses and therapeutic strategies for gait disorders in Parkinson's disease].

Devos D, Bordet R, Defebvre L.

Rev Neurol (Paris) · 2009-10-06

DOI: 10.1016/j.neurol.2009.07.017PMID: 19811797

USE OF 4-CYCLOPROPYLMETHOXY-N-(3,5-DICHLORO-1-OXIDOPYRIDIN-4-YL)-5-(METHOXY)PYRIDINE-2-CARBOXAMIDE FOR THE TREATMENT OF MOTOR DISORDERS RELATED TO PARKINSON'S DISEASE

DELAY-GOYET PHILIPPE, DELGORGE CLAIRE, MENET CHRISTINE, POUGHON GILLES, RAVINET-TRILLOU CHRISTINE.

· 2009-10-05

Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease.

Clarke CE, Worth P, Grosset D, Stewart D.

Parkinsonism Relat Disord · 2009-10-04

DOI: 10.1016/j.parkreldis.2009.09.005PMID: 19805000

Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems.

Kim TK, Kang W, Chun IK, Oh SY, Lee YH, Gwak HS.

Eur J Pharm Sci · 2009-10-03

DOI: 10.1016/j.ejps.2009.09.019PMID: 19804823

Enhanced alpha-synuclein expression in human neurodegenerative diseases: pathogenetic and therapeutic implications.

McCormack AL, Di Monte DA.

Curr Protein Pept Sci · 2009-10-01

DOI: 10.2174/138920309789351912PMID: 19538156

Goal attainment after treatment of parkinsonian camptocormia with botulinum toxin.

Fietzek UM, Schroeteler FE, Ceballos-Baumann AO.

Mov Disord · 2009-10-01

DOI: 10.1002/mds.22676PMID: 19645067

Suicide following duodenal levodopa infusion for Parkinson's disease.

Santos-García D, Macías M, Llaneza M, Aneiros A.

Mov Disord · 2009-10-01

DOI: 10.1002/mds.22708PMID: 19645071